MOLINA HEALTHCARE, INC.

Molina Healthcare maintains a strong liquidity position with $5.42 billion in cash and equivalents as of March 31, 2026, and a current ratio of 1.63, indicating sufficient short-term liquidity to cover obligations. The company's free cash flow of $1.06 billion and operating cash flow of $1.08 billion suggest robust cash generation. However, the debt-to-equity ratio of 0.92 indicates moderate leverage, with long-term debt of $3.77 billion. Profitability metrics show a return on equity of 0.34% and a return on assets of 0.09%, both below the industry median for managed healthcare providers. Operating income of $83 million in Q1 2026 represents a significant decline from $433 million in the same period in 2025, primarily due to increased medical care costs and an impairment charge of $93 million related to the MAPD product. The company's revenue is concentrated in four segments: Medicaid, Medicare, Marketplace, and Other. Medicaid and Medicare are the primary revenue drivers, with Medicaid accounting for the largest share. The company's geographic exposure is concentrated in California, New York, Texas, and Washington, where its health plans operate at a larger scale. Molina Healthcare's revenue growth has slowed, with Q1 2026 revenue of $10.8 billion compared to $11.15 billion in Q1 2025. The company plans to focus on dual-eligible members in Medicare and has announced the exit of the MAPD product for 2027. Strategic priorities include organic growth, inorganic acquisitions, and returning excess capital to shareholders through share repurchase programs. The company faces medium dilution risk, with a dilution potential of 1.9% (basic shares outstanding of 52 million vs. diluted shares of 51 million). Adjustments in the valuation model reflect the impairment charge and the strategic shift in Medicare products. Recent filings highlight forward-looking statements and risk factors, including the impact of AI administrative tools, pharmacy costs, and the transition of Medicare-Medicaid pilot programs. The company also faces risks related to state Medicaid waivers, vaccine hesitancy, and potential new epidemics.